Belimumab subcutaneous in Chinese pediatric SLE

Phase 1, open-label, single-arm trial of belimumab in systemic lupus erythematosus (SLE), sponsored by GSK. Primary endpoints: Area Under the Curve at Steady-state to the End of the Dosing Period for Participants Weighing ≥50 kg at Day 85, Area Under the Curve at Steady-state to the End of the Dosing Period for Participants Weighing Between 30 kg and <50 kg at Day 81 and 10 more. Started Jul 2023; status: completed.